Pfizer files paediatric Lipitor in the EU
This article was originally published in Scrip
Executive Summary
Pfizer has filed a paediatric 5mg formulation of Lipitor (atorvastatin) with the EMEA for the treatment of six to 18 year-old patients with familial hypercholesterolemia, a rare genetic disorder that causes high LDL-cholesterol levels and increased heart disease risk.